Cover Image
Market Research Report
Product code
955324

Global Alopecia Treatment Market, Size, Share, Opportunities and Forecast, 2020-2027

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Alopecia Treatment Market, Size, Share, Opportunities and Forecast, 2020-2027
Published: April 3, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • ALL
  • Description
  • Table of Contents
Description

Global Alopecia Treatment Market is segmented By Disease Type (Androgenic Alopecia, Alopecia Areata, Cicatricial Alopecia, Traction Alopecia, Alopecia Totalis, Alopecia Universalis, Others), By Gender (Male, Female), By Drug Type (Topical Agents, Corticosteroids, Immunosuppressants, Others), By Route of Administration (Oral, Topical, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Alopecia Treatment Market is expected to grow at a high CAGR of 5.5% during the forecasting period (2020-2027).

Alopecia is the partial or complete loss of hair, especially on the scalp, entire head, or the entire body. It is classified into different types as the alopecia areata, androgenic alopecia, alopecia totalis, traction alopecia, alopecia Universalis, and cicatricial alopecia. It occurred due to heredity, hormonal changes, medical conditions, or a normal part of aging. Drugs, hair transplant, and laser therapy are used for the treatment of Alopecia. 

  • Source: DataM Intelligence Analysis

Market Dynamics:

The market is driven by the increasing demand for Alopecia treatment with the increasing prevalence of Alopecia due to the increasing consumption of tobacco and alcohol. Several factors, such as aging and hormonal anomalies, lead to the development of Alopecia. The growing prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism, shall stimulate market growth.

There is increasing research and development activities for the development of Alopecia therapies. The expected approval of emerging therapies shall stimulate market growth. For instance, in July 2020, Concert Pharmaceuticals, Inc. had received the Breakthrough Therapy Designation for the oral Janus kinase inhibitor, CTP-543, to treat adult patients with moderate-to-severe alopecia areata. The clinical trial has demonstrated that the use of the CTP-543 among patients with moderate-to-severe alopecia areata. The patients were treated with either 8 mg twice-daily or 12 mg twice-daily of CTP-543. CTP-543 has met the primary efficacy endpoint with statistically significant differences relative to placebo in the patients achieving a ≥ 50% relative change from baseline at 24 weeks as measured by the Severity of Alopecia Tool (SALT). CTP-543 was generally well tolerated. Only one serious adverse event was reported among the patients.

In March 2020, Eli Lilly had received the breakthrough therapy designation from the United Food and Drug Administration (FDA) for baricitinib to treat alopecia areata. Baricitinib is the once-daily oral JAK inhibitor. The Phase II trial of the baricitinib conducted among the patients with the alopecia areata demonstrated no new safety signals with no serious adverse events. Only mild or moderate treatment-emergent adverse events (TEAEs) were observed among the patients.

Several organizations, associations, and institutes are involved in researching the management and treatment of alopecia. For instance, The National Alopecia Areata Foundation (NAAF) is a nonprofit organization involved in raising awareness regarding the alopecia areata. NAAF supports research to find a cure or acceptable treatment for alopecia areata, supports those with the disease, and educates the public about alopecia areata. This organization provides support, awareness & advocacy, and research to find a treatment or cure for alopecia.

 Segment Analysis

The Alopecia Treatment market is segmented based on the disease type as Androgenic Alopecia, Alopecia Areata, Cicatricial Alopecia, Traction Alopecia, Alopecia Totalis, Alopecia Universalis, and Others. The Alopecia Areata segment accounts for the highest market due to the high prevalence of Alopecia Areata. According to the National Alopecia Areata, approximately 147 million people are affected by alopecia areata worldwide. Alopecia Areata is presented with discrete, smooth patches of alopecia on the scalp. It also occurs in other hair-bearing areas, such as the eyebrows, eyelashes, beard, and extremities. Alopecia Areata is prevalent among patients with autoimmune diseases, i.e., Down's syndrome, diabetes, and hyperthyroidism. It can progress into the alopecia Universalis and totalis. Several companies are focusing on developing therapies for the treatment of Alopecia Areata. There is the presence of a promising pipeline for the treatment of Alopecia Areata. For instance, in January 2019, Pfizer Inc. had initiated the Phase II/III trial of oral JAK3 inhibitor, PF-06651600, to treat patients with moderate to severe alopecia areata.

Further, the alopecia treatment market is also classified based on gender as the male and female. Alopecia is most common among the male in comparison to the female. According to the American Hair Loss Association, around 50% of males experience some hair fall by 50 years. Androgen is a leading cause of androgenetic alopecia among males. The increasing prevalence of Polycystic ovary syndrome (PCOS), the number of cosmetic practices, and unhealthy lifestyles are the major factors leading to Alopecia among females.

  • *Source: DataM Intelligence Analysis

Geographical Presentation

By region, the Alopecia Treatment market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the Alopecia Treatment market due to the high prevalence of Alopecia. According to the National Alopecia Areata, approximately 6.8 million people are affected by alopecia areata in the United States. According to the American Hair Loss Association, approximately 95% of hair loss occurred due to androgenetic alopecia among men. Several public and private companies raise the investment for the research and development activities for the novel therapies to treat Alopecia. There is growing innovation for the development of therapies for the treatment of Alopecia. The high prevalence of acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism shall stimulate market growth.

Asia-Pacific is expected to have positive market growth due to Alopecia's treatment and management's increasing awareness. There is increasing technological advancement for the development of novel therapies for the treatment of Alopecia. The increasing purchasing power and domestic income of the people shall boost Alopecia treatment demand over the forecasted period.

  • *Source: DataM Intelligence Analysis

Competitive Analysis

The Alopecia Treatment market is highly competitive with the presence of several international and local market players. Disease diversification, technological advancement, revenue generation, and opportunities intensify the market competition. Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., and Sun Pharmaceuticals Industries Ltd are the leading market players with significant market share.

Companies are using product development, research and development, technology advancement, and market expansion strategies for holding their position in the market. For instance, in June 2020, Follica, Inc. had received positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase III development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

In December 2019, Follica, Inc. had announced the topline results from its safety and efficacy optimization study to treat hair loss in male androgenetic alopecia. The study was designed to select the optimal treatment regimen using Follica's proprietary device combined with a topical drug and successfully met its primary endpoint. The treatment regimen demonstrated a statistically significant 44% improvement of visible hair count after three months of treatment compared to baseline. The overall improvement of visible hair count after three months of treatment was 29% compared to baseline, and a substantially improved outcome was seen with the optimal treatment regimen.

In July 2019, Aclaris Therapeutics, Inc. had announced the results from its Phase II clinical trial of ATI-501, an investigational oral Janus Kinase (JAK) 1/3 inhibitor, in subjects with alopecia areata. The clinical trial has demonstrated a statistically significant improvement over placebo in hair growth measures, including the primary endpoint and certain secondary endpoints of the trial. ATI-501 was observed to be generally well-tolerated at all doses. No serious adverse events were reported among the patients. Nasopharyngitis, influenza, upper respiratory tract infection, urinary tract infection, acne, blood creatine phosphokinase increased, and sinusitis were the most common adverse events observed among the patients.

In September 2018, Pfizer Inc. had received the Breakthrough Therapy designation from the United States Food and Drug Administration (FDA) for PF-06651600 to treat alopecia areata. PF-06651600 is an oral small molecule that selectively inhibits Janus kinase (JAK) 3. PF-06651600 had met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline at week 24 as measured by the Severity of Alopecia Tool (SALT) score.

Why Purchase the Report?

Visualize the Alopecia Treatment market's composition in terms of disease type, gender, drug type, administration route, and distribution channel, highlighting the critical commercial assets and players.

Identify commercial opportunities in the Alopecia Treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global Alopecia Treatment market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • *The global Alopecia Treatment market report will provide access to approximately 53 Market data tables, 44 figures, and 178 pages

Target Audience

Industry Investors/Investment Bankers

Suppliers/Buyers

Education & Research Institutes

Manufacturers

Research Professionals

Emerging Companies

Distributors

Related Topic's

Alopecia Medication Market

Alopecia Therapeutics Market

Table of Contents

Table of Contents

Table of Contents

Alopecia Treatment Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Alopecia Treatment Market - Market Definition and Overview

Alopecia Treatment Market - Executive Summary

Market Snippet By Disease Type

Market Snippet By Gender

Market Snippet By Drug Type

Market Snippet By Route of Administration

Market Snippet By Distribution Channel

Market Snippet by Region

Alopecia Treatment Market -Dynamics

Market Impacting Factors

Drivers

 Restraints

Impact Analysis

Opportunity

Alopecia Treatment Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Regulatory Analysis

Pricing Analysis

Alopecia Treatment Market - By Disease Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Attractiveness Index, By Disease Type

Androgenic Alopecia*

Introduction

Market Size Analysis, USD Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026

Alopecia Areata

Cicatricial Alopecia

Traction Alopecia

Alopecia Totalis

Alopecia Universalis

Others

Alopecia Treatment Market - By Gender

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender

Market Attractiveness Index, By Gender

Male*

Introduction

Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026

Female

Alopecia Treatment Market - By Drug Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender

Market Attractiveness Index, By Gender

Topical Agents*

Introduction

Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026

Corticosteroids

Immunosuppressants

Others

Alopecia Treatment Market - By Route of Administration

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Attractiveness Index, By Route of Administration

Oral*

Introduction

Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026

Topical

Injectable

Alopecia Treatment Market - By Distribution Channel

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Attractiveness Index, By Distribution Channel

Hospital Pharmacies*

Introduction

Market Size Analysis, USD Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026

Retail Pharmacies

Online Pharmacies

Others

Alopecia Treatment Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

The U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

The U.K.

France

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

The Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Gender

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration.

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

 Alopecia Treatment Market Competitive Landscape

Competitive Scenario

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Alopecia Treatment Market Company Profiles

Aclaris Therapeutics Inc.*

Company Overview

Form Portfolio and Description

Key Highlights

Financial Overview

Cipla Inc.

Concert Pharmaceuticals Inc.

Daiichi Sankyo Inc.

GlaxoSmithKline PLC

HCell Inc.

Johnson & Johnson

Merck & Co. Inc.

Sun Pharmaceuticals Industries Ltd

Lexington Intl., LLC (*List Is Not Exhaustive)

Alopecia Treatment Market - Premium Insights

Alopecia Treatment Market - DataM

Appendix

About Us and Services

Contact Us